Search

The rechargeable zinc-air batteries (ZABs) are promising energy storage devices, but their performance is limited by the air electrode, coming from the contradictory wettability requirements of the air electrode at charging and discharging. Herein, to improve the mass transport and adapt to its different requirements when charging and discharging the ZABs, a Janus air electrode was fabricated with a void-rich, superaerophobic oxygen evolution reaction catalytic layer and a dense superhydrophobic oxygen reduction reaction catalytic layer. The ZAB using the Janus air electrode exhibits a low voltage gap of 0.78 V for charging and discharging at 10 mA cm

UM-164 is a dual inhibitor of c-Src and p38 MAPK, and has been a lead compound for targeting triple-negative breast cancer. UM-164 shows stronger binding to the active sites of Src compared with the conventional Src inhibitor Dasatinib. While Dasatinib has displayed some inhibitory effects on glioma growth in clinical trials, whether UM-164 can suppress glioma growth has not been reported. Here we show that UM-164 suppressed the proliferation, migration and spheroid formation of glioma cells, and induced cell cycle arrest in the G1 phase. Moreover, UM-164 triggered YAP translocation to the cytoplasm and reduced the activity of YAP, as evidenced by a luciferase assay. Accordingly, UM-164 markedly decreased the expression levels of YAP target genes CYR61 and AXL. Importantly, ectopic expression of wild-type YAP or YAP-5SA (YAP constitutively active mutant) could rescue the anti-proliferative effect induced by UM-164. Intriguingly, p38 MAPK appears to play a greater role than Src in UM-164-mediated inhibition of YAP activity. Furthermore, the in vitro anti-glioma effect mediated by UM-164 was confirmed in a xenograft glioma model. Together, these findings reveal a mechanism by which UM-164 suppresses the malignant phenotypes of glioma cells and might provide a rationale for UM-164-based anti-glioma clinical trials.

The electrochemical CO2 reduction reaction (CO2RR) offers an environmentally benign pathway for renewable energy conversion and further regulation of the environmental CO2 concentration to achieve carbon cycling. However, developing desired electrocatalysts with high CO Faradaic efficiency (FECO) at an ultralow overpotential remains a grand challenge. Herein, we report an effective CO2RR electrocatalyst that features Ag single-atom coordinated with three nitrogen atoms (Ag1-N3) anchored on porous concave N-doped carbon (Ag1-N3/PCNC), which is identified by X-ray absorption spectroscopy. Ag1-N3/PCNC shows a low CO2RR onset potential of -0.24 V, high maximum FECO of 95% at -0.37 V, and high CO partial current density of 7.6 mA cm-2 at -0.55 V, exceeding most of the previous Ag electrocatalysts. The in situ infrared absorption spectra technique proves that Ag1-N3 single-atom sites have sole linear-adsorbed CO and can easily desorb *CO species to achieve the highest CO selectivity in comparison with the corresponding counterparts. This work provides significant inspiration on boosting CO2RR by tuning the active center at an atomic level to achieve a specific absorption with an intermediate.

The electrochemical CO2 reduction reaction (CO2RR) is of importance for reducing global CO2 emissions. Herein, we reported a highly active CO2RR catalyst, namely Co–N–Ni/NPCNSs, which is considered as an advanced single-site catalyst with Co–N–Ni bimetallic sites connected by a N bridge between Co and Ni. The N-bridged Co–N–Ni bimetallic sites were confirmed by the X-ray absorption spectroscopy. The Co–N–Ni/NPCNSs catalyst shows a higher turnover frequency of 2049 h−1 at a low overpotential of 370 mV and CO faradaic efficiency of 96.4% compared to that of Co–N/NPCNSs (1205 h−1 and 61.5%) and Ni–N/NPCNSs (404 h−1 and 45.0%) with single Co–N4 and Ni–N4 sites, respectively. In situ synchrotron radiation Fourier transform infrared spectra and DFT calculations show that N-bridged Co–N–Ni bimetallic sites promote the formation of COOH* intermediates, thus accelerating CO2RR.

A niobate/titanat nanoflakes (Nb/TiNFs) composite was synthesized via the hydrothermal method and used to remove Pb(II) from water. XRD, TEM, and SEM results indicate that Nb/TiNFs appear as nanoflakes, of which the primary crystal phase is tri-titanate. Nb/TiNFs show rapid adsorption kinetics and the result fits well with the pseudo-second order model. The key mechanism of adsorption is ion-exchange between metal and -ONa/H. According to the Langmuir isotherm model, the maximum capacity of Pb(II) is 488.323 mg·g−1. The relatively low RL values indicate that Nb/TiNFs exhibit favorable adsorption of Pb(II). Nb/TiNFs indicate high adsorption capacity over a broad pH range. Co-existing inorganic ions (Na+ and Ca2+) have a slight inhibition effect on adsorption, and HA moderately inhibits the adsorption of Pb(II) on Nb/TiNFs. Because of the simple method of synthesis and high removal efficiency for heavy metals, Nb/TiNFs are a promising material in remediation of heavy metal polluted water.

Oxygen-involved electrochemical reactions are crucial for plenty of energy conversion techniques. Herein, we rationally designed a carbon-based Mn-N2C2 bifunctional electrocatalyst. It exhibits a half-wave potential of 0.915 V versus reversible hydrogen electrode for oxygen reduction reaction (ORR), and the overpotential is 350 mV at 10 mA cm-2 during oxygen evolution reaction (OER) in alkaline condition. Furthermore, by means of operando X-ray absorption fine structure measurements, we reveal that the bond-length-extended Mn2+-N2C2 atomic interface sites act as active centers during the ORR process, while the bond-length-shortened high-valence Mn4+-N2C2 moieties serve as the catalytic sites for OER, which is consistent with the density functional theory results. The atomic and electronic synergistic effects for the isolated Mn sites and the carbon support play a critical role to promote the oxygen-involved catalytic performance, by regulating the reaction free energy of intermediate adsorption. Our results give an atomic interface strategy for nonprecious bifunctional single-atom electrocatalysts.

Recently, vanadium diselenide (VSe2), a member of transition metal dichalcogenides, has attracted a great deal of interest in spintronic devices and memory devices due to its unique physical properties. However, it is still a challenge to prepare a continuous VSe2 thin film which is critical for its potential application. Here, we report a continuous single-crystalline 1T-VSe2 thin film grown on mica by pulsed laser deposition. Both x-ray diffraction and high-resolution transmission electron microscopy verify the van der Waals epitaxy of the VSe2/mica heterostructure. Free-standing and flexible VSe2 thin films can be obtained and combined with integrated circuit technology, which is of great significance for the application of two-dimensional materials in the field of multifunctional flexible electronic devices.

Hypoxia is one of the prominent features of solid tumors. Hypoxia activated prodrugs (HAPs), selectively killing hypoxic cells, possess the potential to transform hypoxia from a nuisance to an advantage in precision therapy. Exhibiting a more significant hypoxic microenvironment, gliomas, as the most frequent and incurable neurological tumors, provide HAPs a more attractive therapeutic prospect. However, the insufficient hypoxia and the obstruction of the blood-brain barrier (BBB) severely limit the activation and bio-availability of HAPs. Herein, a novel nanoparticle iRGD@ZnPc + TPZ was designed and synthesized to achieve gliomas inhibition by encapsulating tirapazamine (TPZ) as a HAP and zinc phthalocyanine (ZnPc) as a photosensitizer to enhance hypoxia. iRGD@ZnPc + TPZ can realize breakthrough BBB, deep penetration, and significant retention in gliomas, which is attributed to the iRGD-mediated receptor targeting and active transport. After being internalized by tumor cells and radiated, ZnPc efficiently consumes intratumoral Osub2/subto produce reactive oxygen species, which not only implements tumor suppression, but also intensify hypoxia to activate TPZ for amplifying chemotherapy. The photosensitizer-enhanced activation of HAPs inhibits gliomas growth. This study provides a new strategy with sensitizing and activating HAPs for gliomas treatment in clinical.

This study is carried out to elucidate the role of long noncoding RNAs (lncRNAs) MT1JP in proliferation, invasion, migration, and apoptosis of glioma cells through the regulation of PTEN/Akt signaling pathway. The expression of MT1JP in 80 normal brain tissues and 138 glioma tissues, as well as glioma cell lines, was detected by quantitative reverse-transcription polymerase chain reaction. Besides, glioma cells with overexpression and low expression of MT1JP were constructed to confirm the role of MT1JP in proliferation, invasion, migration, and apoptosis of glioma cells and the growth of glioma cells in vivo through the regulation of PTEN/Akt signaling pathway. MT1JP expression was downregulated in glioma tissues and cells. The low expression of MT1JP was considered as an independent risk factor for predicting overall survival in gliomas. After transfection of MT1JP overexpression plasmid, glioma cells showed decreased proliferation, migration and invasion ability, increased apoptosis rate, and decreased the tumorigenic ability of nude mice. The trends were opposite in glioma cells transfected with MT1JP poor expression plasmid. Collectively, our study suggests that lncRNA MT1JP is responsible for inhibiting proliferation, invasion, and migration while promoting apoptosis of glioma cells through the activation of PTEN/Akt signaling pathway.

Glioma is the most common malignant tumor of the central nervous system, and it is characterized by high relapse and fatality rates and poor prognosis. Bufalin is one of the main ingredients of Chan-su, a traditional Chinese medicine (TCM) extracted from toad venom. Previous studies revealed that bufalin exerted inhibitory effects on a variety of tumor cells. To demonstrate the inhibitory effect of bufalin on glioma cells and glioma stem-like cells (GSCs) and discuss the underlying mechanism, the proliferation of glioma cells was detected by MTT and colony formation assays following treatment with bufalin. In addition, we investigated whether bufalin inhibits or kills GSCs using flow cytometry, Western blotting, and reverse transcription polymerase chain reaction analysis (RT-PCR). Finally, we investigated whether bufalin could improve the therapeutic effect of temozolomide (TMZ) and discussed the underlying mechanism. Taken together, our data demonstrated that bufalin inhibits glioma cell growth and proliferation, inhibits GSC proliferation, and kills GSCs. Bufalin was found to induce the apoptosis of GSCs by upregulating the expression of the apoptotic proteins cleaved caspase 3 and poly(ADP-ribose) polymerase (PARP) and by downregulating the expression of human telomerase reverse transcriptase, which is a marker of telomerase activity. Bufalin also improved the inhibitory effect of TMZ on GSCs by activating the mitochondrial apoptotic pathway. These results suggest that bufalin damages GSCs, induces apoptosis, and enhances the sensitivity of GSCs to TMZ.

The influence of Dzyaloshinskii–Moriya interaction (DMI) on the vortex reversal driven by an out-of-plane spin-polarized current in an off-centered nanocontact structure is investigated. The simulation results show that DMI plays a vital role in vortex core reversal, including reversal current density, reversal velocity and reversal time. Under the influence of DMI, magnetic vortices still reverse polarity through the nucleation and annihilation of vortex and anti-vortex, with some peculiar characteristics. These results open up new possibilities for the application of magnetic vortex-based spin-transfer encryption nano-storage.

BACKGROUND As the most common and detrimental brain tumor with high invasiveness and poor prognosis, glioblastoma (GBM) has severely threatened people's health globally. Therefore, it is of great importance and necessary to identify the molecular mechanisms involved in tumorigenesis and development, thus contributing to potential therapeutic targets and strategies. METHODS The level of circ_0001588 was detected in 68 pairs of GBM tissues and adjacent normal tissues and human glioma cell lines via a real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Then, the effect of circ_0001588 on the proliferation, migration and invasion of glioma cells was evaluated. In addition, potential downstream targets of circ_0001588 were forecasted by circBANK and Starbase. Their interaction was confirmed by introducing luciferase reporter assays. Moreover, sh-circ_0001588 transfected U251 cells were used to form tumors in vivo. Finally, the functional mechanism of circ_0001588 was identified by qRT-PCR, western blotting, xenograft and immunohistochemistry (IHC) assays. RESULTS The expression of circ_0001588 is markedly up-regulated in GBM tissues and human gliomas cells. Additionally, increased expression of circ_0001588 is positively relevant with poor survival in GBM patients. The down-regulation of circ_0001588 distinctly inhibits the proliferation, migration and invasion of GBM in vitro, as well as tumor growth in vivo. Moreover, knockdown of circ_0001588 reduces the tumor volume and weight, enhances the relative IHC staining index of E-cadherin and decreases the relative IHC staining index of Ki-67, Yin Yang 1 (YY1) and vinmentin in vivo. Mechanistically, circ_0001588 locates in the cytoplasm, which is directly bound with miR-211-5p. Furthermore, circ_0001588 can positively regulate YY1 via sponging miR-211-5p. Moreover, circ_0001588 accelerates the proliferation, migration and invasion of GBM by modulating miR-211-5p/YY1 signaling. CONCLUSIONS These results illustrate a new circ_0001588/miR-211-5p/YY1 regulatory signaling axis in GBM.

The electrochemical CO

Oxygen-involved electrochemical reactions are crucial for plenty of energy conversion techniques. Herein, we rationally designed a carbon-based Mn-N

Doped phosphide is promising in earth-abundant element based catalysts for hydrogen evolution reaction (HER). Here we employ ammonium hypophosphite (NH4H2PO2) to synthesize a novel parallel doped catalyst, nitrogen doped molybdenum phosphide nanoparticles (NPs) supported on nitrogen doped carbon nanotubes (N-MoP/ N-CNTs ). The NH4H2PO2 as a bifunctional agent severs as both phosphidation agent and nitrogen source, which makes the synthetic route simple and efficient. The as-obtained parallel doped N-MoP/N-CNTs show an overpotential of 103±5 mV at 10 mA cm−2, which is 140 mV lower than that of MoP NPs. The enhanced HER performance is attributed to the electronic effect by doped MoP and CNTs supports. This work provides a facile route to synthesize doped phosphides for the potential applications in hydrogen energy.

Ion substitution is considered to be one of the efficient approaches to improve the magnetic properties of the barium hexaferrites. In this work, we fabricated BaFe12−xAlxO19 (x = 0, 1, 2, 4, 6) via a simple auto-combustion method and investigated their structures, morphologies and magnetic properties. The coercivity is greatly affected by annealing temperature and Al3+ content. In addition, the Al3+ substitution sites in BaFe12−xAlxO19 were further investigated by the Mossbauer spectroscopy and the superparamagnetic components were found in the BaFe8Al4O19 and BaFe6Al6O19. The highest coercivity of 13.7 kOe was achieved in the BaFe8Al4O19, which increases by 168.6% compared with that of BaFe12O19. This work opens up a new and meaningful insight for the understanding of microstructure and coercivity mechanism towards the Al3+ substituted barium hexaferrites.

Object: This study is aimed at exploring the correlation between serum adiponectin (ADPN) levels and leukemia. Materials and Methods: Eligible studies were retrieved using both computerized and manual searches. Relevant case-control studies were enrolled in strict accordance to our inclusion and exclusion criteria. Result: We searched 130 published studies and included 11 eligible studies for our meta-analysis according to our rigorous inclusion and exclusion criteria. The selected studies included 637 leukemia patients and 524 healthy controls. Our meta-analysis showed: (1) Serum ADPN levels of patients with leukemia were lower than healthy controls; (2) a subgroup analysis based on sample size verified that serum ADPN levels in patients with leukemia were significantly lower than that in healthy controls irrespective of a large sample size (n ≥ 80) or a small sample size (n < 80). Conclusion: Our meta-analysis suggested that serum ADPN levels may be inversely correlated with leukemia, and ADPN levels can be used as an effective biologic marker in early diagnosis and therapeutic monitoring of leukemia.

MicroRNAs (miRNAs) are small non-coding RNAs that serve pivotal roles in human diseases. Several miRNAs, such as miR-485-3p, have been identified as potential biomarkers for predicting overall survival of patients with glioblastoma (GBM). However, the underlying mechanism of miRNAs in promoting GBM progression remains unknown. In the present study, decreased miR-485-3p expression was detected in tumor tissues from patients with GBM. Using western blot analysis, reverse transcription-quantitative PCR and dual luciferase reporter assay, ring finger protein 135 (RNF135) was confirmed as a target gene of miR-485-3p in GBM cells. Through silencing of RNF135, miR-485-3p inactivated the mitogen-activated protein kinase/ERK1/2 pathway in GBM cells. Moreover, functional assays demonstrated that miR-485-3p inhibited GBM cell proliferation and migration whilst overexpression of RNF135 reversed this effect. Additionally, a negative correlation between miR-485-3p and RNF135 mRNA expression was observed in tissues from patients with glioblastoma. In conclusion, the present results demonstrated that miR-485-3p functioned as a tumor suppressor which suggested that miR-485-3p might have a role in GBM progression.

The development of acquired drug resistance is the primary cause of chemotherapy failure in the treatment of ovarian cancer. To examine the mechanism underlying Taxol (TAX) resistance in ovarian cancer and attempt to reverse it, the present study induced a TAX‑resistant ovarian cancer cell line SKOV3/TAX using a gradient concentration increment method. The properties of the resistant cell line were initially investigated by proliferation, colony formation, adhesion and cell cycle analysis compared with control SKOV3 cells. To examine the mechanism, the expression of p53 upregulated modulator of apoptosis (PUMA) was compared between SKOV3/TAX and SKOV3 cells by western blot analysis. An adenovirus expressing p53 (Ad‑p53), alone or in combination with TAX, was used to treat the drug‑resistant ovarian cancer cells SKOV3/TAX. The effects of Ad‑p53 on pro‑apoptosis and the reversal of drug resistance were evaluated using flow cytometric analysis, cleaved‑poly ADP‑ribose polymerase detection, microscopic observation and MTT measurement. Compared with the control cells, the TAX‑resistant ovarian cancer cell line SKOV3/TAX was characterized by reduced sensitivity to TAX treatment, a significantly slower proliferation rate, higher colony‑forming efficiency and higher adhesion ability. However, no significant difference in cell cycle distribution was identified. PUMA, a potent pro‑apoptotic protein, was markedly suppressed in the SKOV3/TAX cells. Ad‑p53 infection stimulated the upregulation of PUMA and re‑sensitized the resistant ovarian cancer cells to TAX by an apoptotic mechanism. Therefore, Ad‑p53 infection is an effective gene therapy method to re‑sensitize the resistant ovarian cancer cells to TAX by restoring the expression of PUMA.

MicroRNA-374a has been abnormally expressed in several cancer types; however, its role in glioma remains unclear. Therefore, we aimed to investigate whether microR-374a participated in the progression of glioma. Expression of microR-374a in glioma cell lines and normal cell line was measured by quantitative real-time polymerase chain reaction. Luciferase reporter assay and Western blot were used to detect the targets of microR-374a. In vitro functional experiments were conducted to investigate the biological role of microR-374a. Low expression of microR-374a was found in glioma cell lines. Prokineticin 2 was identified as a direct target of microR-374a in glioma. Investigations on the mechanisms related to glioma progression showed that microR-374a inhibited glioma cell proliferation, cell cycle progression, and cell invasion through targeting Prokineticin 2. Taken together, these results revealed that microR-374a functions as tumor suppressor by targeting Prokineticin 2, suggesting it might be a novel therapeutic target for glioma.

Rationale Pegaspargase has been used in the treatment of acute lymphoblastic leukemia with promising results. However, it has also been associated with several potentially serious complications, including thrombosis. Pegaspargase-induced cerebral venous thrombosis and bone marrow necrosis are very rare. Patient concerns A 50-year-old female developed headache, weakness of the right lower extremity, fever, and bone pain after chemotherapy including pegaspargase for the treatment of acute lymphoblastic leukemia. Diagnoses Her imaging studies and bone marrow examinations were compatible with cerebral venous thrombosis and bone marrow necrosis. Interventions The patient received anticoagulation therapy with rivaroxaban. Outcomes After treatment with rivaroxaban, she had a good outcome without major or minor bleeding. Lessons Clinicians should be aware of the very rare but possible induction of bone marrow necrosis during pegaspargase treatment when there is necrosis in other organs. Because of its greater safety and convenience, rivaroxaban gains popularity over traditional anticoagulant drugs.

Gliomatosis cerebri (GC) is a rare glial neoplasm, characterized by extensive diffuse brain infiltration and relative preservation of the underlying architecture. In the present case report, a patient with type 2 GC, which mimicked the clinicoradiological course of acute viral encephalitis, is presented. A 56-year-old male presented with fever, dizziness, headache and numbness in the right extremities three days prior to admission to hospital. The cerebrospinal fluid (CSF) showed mild pleocytosis. Brain magnetic resonance imaging (MRI) revealed hyperintensity on fluid-attenuated inversion recovery images in the left frontal, temporal, insular lobes and in the left thalamus. No signal enhancement was observed following gadolinium administration. The patient was diagnosed with acute viral encephalitis of unknown cause and received a 10-day course of acyclovir, intravenously. At the follow-up three months later, the patient had personality changes and memory deterioration. The results from the follow-up MRI revealed no remarkable changes. At the follow-up six months after presentation, the patient had expressive aphasia and severe headaches. Subsequently, the patient had two tonic-clonic seizure onsets. The results from the MRI showed an increase in lesion size, more edema around the lesion and irregular enhancement in the left frontal lobe. However, the lesions in the left temporal and insular lobes and in the left thalamus were nearly unchanged. Magnetic resonance spectroscopy (MRS) showed elevated choline (Cho)/creatine (Cr) and Cho/N-acetylaspartate (NAA) ratios, as well as decreased NAA/Cr ratios. Surgery was performed and the neuropathological diagnosis of WHO grade III astrocytoma was confirmed. Thus, it is important to pay attention to the differential diagnoses of GC and acute viral encephalitis in patients who have widespread MRI lesions. A brain biopsy is recommended for a diagnosis in this case.

The aim of this study was to analyse the clinical characteristics and laboratory data, treatment and prognosis of polycythemia vera (PV). A retrospective study was performed for 71 PV patients treated in our hospital during January 2001 to July 2011 including analysis of clinical characteristics, laboratory data, myelogram chromosome karyotypes, BCR/ABL and JAK2V617F genes, as well as lactate dehydrogenase (LDH) and neuron-specific enolase (NSE) levels in serum and so on. The results showed that 71 patients (37 males and 34 females with a average age of 57.8 years) were diagnosed. Thrombosis and embolism occurred in 34 patients (47.89%), hemorrhage in 10 patients (14.08%), splenomegaly occurred in 44 patients. The onset of the disease was insidious, 13 patients (18.31%) were found to have PV during the treatments for other diseases. The average hemoglobin at diagnosis was 206.31 (171 - 242) g/L. JAK2V617F mutation was detected in 31 (81.58%) of 38 patients studied. The average levels of serum LDH and NSE were higher than normal and both positively correlated with hemoglobin (P = 0.007, P = 0.005). The disease outcomes were myelofibrosis for 3 patients, death from cerebral hemorrhage for 1 patient, and death from ineffective chemotherapy in 1 patient with ANLL-M2. It is concluded that PV is a chronic myeloproliferative disorder characterized predominantly by thrombosis and hemorrhage. The serum LDH and NSE levels are higher than the normal values. It is inferred that the serum LDH and NSE levels can reflect the degree of malignant proliferation of bone marrow hematopoietic cells and also can be used as an indicator to judge the therapeutic effect of PV.